Supplementary file 1_Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.docx

T-DXd showed the most favorable PFS (HR = 0.18, 95%CI: 0.13–0.25), followed by SHR-A1811 (HR = 0.22, 95%CI: 0.15–0.33) compared with Chem + TKI. SHR-A1811 showed a promising OS signal(HR = 0.31, 95% CI: 0.14–0.69), followed by T-DXd (HR = 0.41, 95% CI: 0.26–0.66) compared with Chem + TKI. For safety, T-DXd exhibited the highest odds for all-grade TRAEs relative to all included control treatments, with statistically significant differences identified when compared with T-DM1 and Chem + TKI., T-DM1 demonstrated better safety characteristics for grade ≥3 TRAEs, with a significantly lower odds of occurrence than SHR-A1811, ARX788, DP303c, and Chem + TKI.</p>Conclusion<p>Included anti-HER2 ADCs significantly improve PFS over Chem + TKI, among which T-DXd and SHR-A1811 deliver notable survival benefits.

Although T-DXd is associated with a higher odd of all-grade TRAEs and T-DM1 exhibits favourable grade ≥3 safety.</p>Systematic Review Registration<p>crd.york.ac.uk/prospero/display_record.php?ID=CRD420251234345, identifier CRD420251234345.</p>